10 high-paying careers where women make up the majority of workers—most pay more than $100,000

Resume Genius identifies top-paying careers where women are ≥50% of workers, led by financial managers (median $161,700) and several health-care roles; notable entries include nurse practitioner ($132,050; 88% women; 35% projected growth 2024–2034), physician assistant ($133,260; 73% women; 20% growth), and speech-language pathologist ($95,410; 95% women; 15% growth). The list highlights a concentration in health care plus roles in HR, PR and finance that combine above-average pay with strong female representation. For investors, the report has minimal near-term market impact but signals sustained structural demand in health-care labor markets and reinforces ESG/diversity considerations for employers and sector allocation decisions.

Analysis

The structural shift toward female-dominated, high-skilled care and management roles is re-shaping labor economics across healthcare, pet care, and corporate services. Expect persistent wage pressure in frontline clinical roles (NP/PA, pharmacists, therapists) driven by constrained education pipelines and aging population demand, which inflates staffing-provider margins while compressing hospital operator EBITDA unless reimbursement or productivity improves. Telehealth and virtual-first care models can arbitrage this by scaling NP/PA productivity across geographies; vendors that standardize workflows and credentialing capture disproportionate value.

Second-order winners include diagnostic platforms for veterinary and outpatient medicine (higher test-per-visit mix), HR/people-ops SaaS sellers as firms invest in retention programs, and specialist staffing marketplaces that reduce hiring friction. Conversely, capital-intensive hospital systems and legacy pharmacy retailers face a two-front squeeze: higher labor cost and margin erosion from route-to-outpatient substitution. Over a 6–24 month horizon, policy (training grants, visa rules) or a surge in supply from accelerated accreditation programs could blunt staffing firms’ pricing power, reversing the premium those vendors now enjoy.

Key tail risks: rapid adoption of automation/AI for routine clinical documentation and some diagnostics could cap wage inflation within 2–5 years; simultaneous macro weakness could depress elective care and pet spending, hitting diagnostics and staffing volumes. Monitor enrollment trends in NP/PA/PharmD programs, state scope-of-practice changes, and telehealth utilization metrics as immediate catalysts that will drive revenue trajectories for platform and staffing names over quarters rather than years.

Key Decisions for Investors

• Long AMN Healthcare Services (AMN) 6–12 months — rationale: benefits from sustained clinical staffing shortages and higher per-diem nurse/NP rates. Position: buy shares or 6–12 month 1.1x delta call spread sized to 2–4% portfolio. Risk/reward: downside limited to ~15% draw if hospitals cut temps quickly; upside ~25–40% if utilization and rates stay elevated.
• Pair trade: Long IDEXX Laboratories (IDXX) / Short a large hospital operator (HCA) 12–24 months — rationale: IDXX captures secular increase in vet diagnostics and outpatient tests; HCA bears margin pressure from staffing inflation and outpatient migration. Position: equal dollar notional longs/shorts. Risk/reward: asymmetric — 15–30% upside on IDXX with 10–20% downside protection via short HCA if macro softens.
• Long UnitedHealth Group (UNH) 6–12 months — rationale: payer-owned primary-care and virtual platforms scale NP/PA labor efficiently and protect margins through care-model control. Position: buy shares or buy-the-dip opportunities; target total return 10–20% with downside tied to near-term claims volatility.
• Tactical allocation to gender-diversity ETF (SHE) 3–12 months — rationale: companies with sustained female leadership/performance tilt likely to benefit from lower turnover and targeted human-capital investments. Position: modest overweight (1–2% portfolio). Risk/reward: defensive equity exposure with potential to outperform broad market by 5–10% in a stable growth scenario; underperforms in a cyclical growth rebound that favors commodity/ex-growth names.